96 related articles for article (PubMed ID: 1735567)
1. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study.
Voto LS; Lapidus AM; Catuzzi P; Uranga Imaz F; Zin C; Margulies M
Hypertension; 1992 Feb; 19(2 Suppl):II132-6. PubMed ID: 1735567
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
3. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
McTavish D; Young RA; Clissold SP
Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
[TBL] [Abstract][Full Text] [Related]
4. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Catalano M; Parini J; Romano M; Libretti A
Eur J Clin Pharmacol; 1985; 28(2):135-8. PubMed ID: 3886402
[TBL] [Abstract][Full Text] [Related]
5. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive activity of cadralazine in experimental hypertensive rats.
Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
[TBL] [Abstract][Full Text] [Related]
7. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.
Catalano M; Parini J; Libretti A
Eur J Clin Pharmacol; 1983; 24(2):157-61. PubMed ID: 6840161
[TBL] [Abstract][Full Text] [Related]
8. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
Antonicelli R; Savonitto S; Tomassini PF; Gambini C; Sardina M; Paciaroni E
Int J Clin Pharmacol Ther; 1994 Apr; 32(4):198-203. PubMed ID: 8032580
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor.
Luzi G; Caserta G; Iammarino G; Clerici G; Di Renzo GC
Ultrasound Obstet Gynecol; 1999 Aug; 14(2):101-9. PubMed ID: 10492869
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs.
Higashio T; Tsuji Y; Nakao K; Sakaguchi S; Tanaka M
Arzneimittelforschung; 1988 Mar; 38(3):350-8. PubMed ID: 3382459
[TBL] [Abstract][Full Text] [Related]
13. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.
Caponnetto S; Valvo E; Mocarelli P; Alberti D; Savonitto S
Eur J Clin Pharmacol; 1991; 40(5):461-5. PubMed ID: 1679390
[TBL] [Abstract][Full Text] [Related]
14. Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy.
Feiks A; Grünberger W; Meisner W
Am J Hypertens; 1991 Feb; 4(2 Pt 2):200S-202S. PubMed ID: 1827022
[TBL] [Abstract][Full Text] [Related]
15. Preeclampsia: an update.
Lambert G; Brichant JF; Hartstein G; Bonhomme V; Dewandre PY
Acta Anaesthesiol Belg; 2014; 65(4):137-49. PubMed ID: 25622379
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cilazapril in elderly patients with essential hypertension. A multicenter study.
Kobrin I; Ben-Ishay D; Bompani R; Dixon R; Hoverman RJ; Jones RW; Kögler P; Sanchez R
Am J Med; 1989 Dec; 87(6B):33S-36S. PubMed ID: 2532458
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies.
Scardo JA; Vermillion ST; Hogg BB; Newman RB
Am J Obstet Gynecol; 1996 Aug; 175(2):336-8; discussion 338-40. PubMed ID: 8765250
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular response to exercise and regional haemodynamics during treatment with prizidilol hydrochloride (SK & F 92 657) in moderately severe essential hypertension.
Andersson O; Ljungman S; Berglund G
Eur J Clin Pharmacol; 1983; 25(5):577-80. PubMed ID: 6662157
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cadralazine in hypertensive patients.
Leonetti G; Parini J; Visconti M; Gradnik R
Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
